Needham Reiterates Buy on Taysha Gene Therapies, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a Buy rating on Taysha Gene Therapies (NASDAQ:TSHA) and maintained a $7 price target.
June 17, 2024 | 10:00 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Gil Blum has reiterated a Buy rating on Taysha Gene Therapies and maintained a $7 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a $7 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100